The STAT3 activation was correlated with increases in expression of PD-L1 in NLTCL and PTCL [58,59]; thus, the combination of JAK/STAT inhibitors with PD1/PD-L1 antibodies could be a promising therapeutic strategy to explore. Here, CD274 is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.